The Acute Promyelocytic Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Promyelocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Promyelocytic Leukemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Promyelocytic Leukemia and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Acute Promyelocytic Leukemia by ten companies/universities/institutes. The top development phase for Acute Promyelocytic Leukemia is discovery with four drugs in that stage. The Acute Promyelocytic Leukemia pipeline has nine drugs in development by companies and two by universities/ institutes. Some of the companies in the Acute Promyelocytic Leukemia pipeline products market are: Phebra, University of Hong Kong and IFOM-IEO Campus.
The key targets in the Acute Promyelocytic Leukemia pipeline products market include DNA, Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA), and Retinoic Acid Receptor RXR Alpha (Nuclear Receptor Subfamily 2 Group B Member 1 or Retinoid X Receptor Alpha or NR2B1 or RXRA).
The key mechanisms of action in the Acute Promyelocytic Leukemia pipeline product include DNA Synthesis Inhibitor with three drugs in Phase II. The Acute Promyelocytic Leukemia pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Acute Promyelocytic Leukemia pipeline products market including Small Molecule, and Monoclonal Antibody.
Acute Promyelocytic Leukemia overview
Acute Promyelocytic Leukemia is an aggressive blood cancer affecting the white blood cells known as promyelocytes which are immature white blood cells. It is characterized by thrombocytopenia (low platelets) resulting in thrombosis, excess bleeding, and anemia. It is a sub type of AML (acute myeloid leukemia) and is a medical emergency condition. Infections, bruises, bleeding are common symptoms and when examined blood the levels of platelets, WBC cells are low known as pancytopenia. Retinoids are common class of drugs for treating APL. Tretinoin is commonly prescribed alone or with chemotherapy regimen anthracycline given intravenously. Supportive care also provided as needed.
For a complete picture of Acute Promyelocytic Leukemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
